Apimeds Pharmaceuticals US (APUS) Stock: Buy, Sell, or Hold?
APUS - Apimeds Pharmaceuticals US, Inc.
$3.22
-0.88 (-21.46%)
▼
5d:
-55.59%
30d:
+22.43%
90d:
+274.42%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When APUS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: APUS is down 55.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: APUS is down 55.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: APUS is currently trading at $3.22, which is considered extended relative to its 30-day fair value range of $1.74 to $4.85.
Technical Outlook: Technically, APUS is in a uptrend. Immediate support is located at $1.61, while resistance sits at $9.14. Short-term momentum is weak, with the stock down 21.5% recently.
Market Sentiment: APUS scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, APUS is in a uptrend. Immediate support is located at $1.61, while resistance sits at $9.14. Short-term momentum is weak, with the stock down 21.5% recently.
Market Sentiment: APUS scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.74 -
$4.85
Company Quality Score
37/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
5.9%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (15/100)
- BEARISH: Downward momentum (-21.5%)
- WARNING: Composite score 37/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.74 -
$4.85
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.61
Resistance Level
$9.14
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Share & Embed Analysis
Last updated: October 03, 2026 6:28 AM ET
Data refreshes hourly during market hours. Next update: 7:28 AM
Data refreshes hourly during market hours. Next update: 7:28 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is APUS showing a specific setup today?
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 47 HOLD |